Analysen von Michael J. Yee
| 31.05.12 | Ariad Pharmaceuticals outperform | RBC Capital Markets | |
| 30.05.12 | Biogen outperform | RBC Capital Markets | |
| 30.05.12 | Sunesis Pharmaceuticals outperform | RBC Capital Markets | |
| 23.05.12 | InterMune sector perform | RBC Capital Markets | |
| 21.05.12 | Celgene outperform | RBC Capital Markets | |
| 18.05.12 | Seattle Genetics outperform | RBC Capital Markets | |
| 18.05.12 | Pharmacyclics outperform | RBC Capital Markets | |
| 18.05.12 | Aveo Pharmaceuticals outperform | RBC Capital Markets | |
|
Werbung
|
|||
| 18.05.12 | ArQule outperform | RBC Capital Markets | |
| 17.05.12 | Sunesis Pharmaceuticals sector perform | RBC Capital Markets | |
| 17.05.12 | Auxilium Pharmaceuticals outperform | RBC Capital Markets | |
| 17.05.12 | Dendreon sector perform | RBC Capital Markets | |
| 10.05.12 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
| 10.05.12 | Dendreon sector perform | RBC Capital Markets | |
| 07.05.12 | ArQule outperform | RBC Capital Markets | |
| 07.05.12 | Xoma outperform | RBC Capital Markets | |
| 07.05.12 | XenoPort outperform | RBC Capital Markets | |
| 03.05.12 | Biogen outperform | RBC Capital Markets | |
| 02.05.12 | Gilead Sciences outperform | RBC Capital Markets | |
| 26.04.12 | Amgen outperform | RBC Capital Markets | |
| 24.04.12 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
| 24.04.12 | Gilead Sciences outperform | RBC Capital Markets | |
| 24.04.12 | InterMune sector perform | RBC Capital Markets | |
| 19.04.12 | Cubist Pharmaceuticals outperform | RBC Capital Markets | |
| 18.04.12 | ArQule outperform | RBC Capital Markets | |
| 18.04.12 | Auxilium Pharmaceuticals outperform | RBC Capital Markets | |
| 17.04.12 | Human Genome Sciences sector perform | RBC Capital Markets | |
| 16.04.12 | Ariad Pharmaceuticals outperform | RBC Capital Markets | |
| 12.04.12 | Dendreon sector perform | RBC Capital Markets | |
| 10.04.12 | ArQule outperform | RBC Capital Markets | |
| 10.04.12 | InterMune sector perform | RBC Capital Markets | |
| 03.04.12 | Amgen outperform | RBC Capital Markets | |
| 03.04.12 | Biogen outperform | RBC Capital Markets | |
| 03.04.12 | Celgene outperform | RBC Capital Markets | |
| 28.03.12 | Elan outperform | RBC Capital Markets | |
| 26.03.12 | United Therapeutics sector perform | RBC Capital Markets | |
| 23.03.12 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
| 22.03.12 | Ariad Pharmaceuticals outperform | RBC Capital Markets | |
| 20.03.12 | Gilead Sciences outperform | RBC Capital Markets | |
| 20.03.12 | Biogen outperform | RBC Capital Markets | |
| 20.03.12 | Celgene outperform | RBC Capital Markets | |
| 20.03.12 | Xoma outperform | RBC Capital Markets | |
| 13.03.12 | Ariad Pharmaceuticals outperform | RBC Capital Markets | |
| 13.03.12 | Biogen outperform | RBC Capital Markets | |
| 13.03.12 | InterMune outperform | RBC Capital Markets | |
| 07.03.12 | Elan outperform | RBC Capital Markets | |
| 06.03.12 | Spectrum Pharmaceuticals outperform | RBC Capital Markets | |
| 06.03.12 | ArQule outperform | RBC Capital Markets | |
| 01.03.12 | Ariad Pharmaceuticals outperform | RBC Capital Markets | |
| 01.03.12 | Aveo Pharmaceuticals outperform | RBC Capital Markets | |